Literature DB >> 14612933

Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.

Stephen Lam1, Xiaochun Xu, Helga Parker-Klein, Jean C Le Riche, Calum Macaulay, Martial Guillaud, Andy Coldman, Adi Gazdar, Reuben Lotan.   

Abstract

Epidemiological studies suggested that vitamin A may be protective against lung cancer, however, recent chemoprevention trials with beta-carotene, a precursor of vitamin A, demonstrated enhancement of lung carcinogenesis among smokers. Whether vitamin A is beneficial or harmful in chemoprevention of lung cancer in smokers has not been resolved. This study was designed to determine the effect of retinol alone in current and former smokers using bronchial dysplasia, nuclear morphometry and retinoic acid receptor-beta (RAR-beta) mRNA expression as surrogate end-point biomarkers (SEBs). Eighty-one current or former smokers with a smoking history of >/=30 pack-years were randomized to receive either placebo or retinol (50,000 IU per day) for six months. Fluorescence bronchoscopy was performed prior to treatment to localize areas suggestive of dysplasia. At least 4 bronchial biopsies were taken per subject including at least two biopsies from apparently normal areas. The same areas were precisely re-biopsied after 6 months. Any new areas suggestive of dysplasia were also biopsied. Changes in the SEBs were assessed before and after treatment. At baseline, the frequency of biopsies negative for RAR-beta expression was: normal (23%), hyperplasia (28%), metaplasia (41%), mild dysplasia (41%), and moderate/severe dysplasia (44%). There was no significant difference in the regression rate between the retinol and placebo groups using histopathology and nuclear morphometry as SEBs. The likelihood of regression was found to be lower in those who continued to smoke during the study (OR=1.86 for those smoking >10 cigarettes per day, p=0.084 to OR=0.95, p=0.26 for those smoking 20+ per day compared to ex-smokers). Retinol was not effective in the up-regulation of RAR-beta in lesions with bronchial dysplasia. We postulate that the lack of effect of retinol on RAR-beta expression among individuals who continued to smoke while taking retinol may be due to suppressive effect of tobacco smoke constituents on RAR-beta expression and/or altered cellular metabolism of retinol to retinoic acid and its isomers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612933

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

Review 1.  Natural history of bronchial preinvasive lesions.

Authors:  Taichiro Ishizumi; Annette McWilliams; Calum MacAulay; Adi Gazdar; Stephen Lam
Journal:  Cancer Metastasis Rev       Date:  2010-03       Impact factor: 9.264

Review 2.  Novel management of oral cancer: a paradigm of predictive oncology.

Authors:  Jon Sudbø
Journal:  Clin Med Res       Date:  2004-11

3.  Potential use of quantitative tissue phenotype to predict malignant risk for oral premalignant lesions.

Authors:  Martial Guillaud; Lewei Zhang; Catherine Poh; Miriam P Rosin; Calum MacAulay
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

4.  In vivo optical coherence tomography imaging of preinvasive bronchial lesions.

Authors:  Stephen Lam; Beau Standish; Corisande Baldwin; Annette McWilliams; Jean leRiche; Adi Gazdar; Alex I Vitkin; Victor Yang; Norihiko Ikeda; Calum MacAulay
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

5.  A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.

Authors:  Stephen Lam; Sumithra J Mandrekar; Yaron Gesthalter; Katie L Allen Ziegler; Drew K Seisler; David E Midthun; Jenny T Mao; Marie Christine Aubry; Annette McWilliams; Don D Sin; Tawimas Shaipanich; Gang Liu; Evan Johnson; Andrea Bild; Marc E Lenburg; Diana N Ionescu; John Mayo; Joanne Eunhee Yi; Henry Tazelaar; William S Harmsen; Judith Smith; Avrum E Spira; Jennifer Beane; Paul J Limburg; Eva Szabo
Journal:  Cancer Prev Res (Phila)       Date:  2016-09-22

6.  Randomized phase II trial of sulindac for lung cancer chemoprevention.

Authors:  Paul J Limburg; Sumithra J Mandrekar; Marie Christine Aubry; Katie L Allen Ziegler; Jun Zhang; Joanne E Yi; Michael Henry; Henry D Tazelaar; Stephen Lam; Annette McWilliams; David E Midthun; Eric S Edell; Otis B Rickman; Peter Mazzone; Melvyn Tockman; John F Beamis; Carla Lamb; Michael Simoff; Charles Loprinzi; Eva Szabo; James Jett
Journal:  Lung Cancer       Date:  2012-12-20       Impact factor: 5.705

7.  Antitumor effect of retinoic acid receptor-beta2 associated with suppression of cyclooxygenase-2.

Authors:  Shumei Song; Baoxiang Guan; Taoyan Men; Ashraful Hoque; Reuben Lotan; Xiao-Chun Xu
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-03

Review 8.  Role of retinoic receptors in lung carcinogenesis.

Authors:  Krisztina Bogos; Ferenc Renyi-Vamos; Gabor Kovacs; Jozsef Tovari; Balazs Dome
Journal:  J Exp Clin Cancer Res       Date:  2008-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.